Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS

Translational optoelectronic control of cardiac rhythm in atrial fibrillation

Project description

Optoelectronic heart rhythm control for atrial fibrillation treatment

The EU-funded TransRhythm project aims to determine the translational potential of optoelectronic heart rhythm control for managing atrial fibrillation (AF) as the most prevalent cardiac arrhythmia. Immortalised human atrial cardiomyocytes expressing light-gated ion channels will be used to engineer human atrium-sized 3D models of AF. Multi-electrode-LED arrays will be integrated to control model optoelectronic rhythm via bioelectricity generation by precise illumination. Insights from the study will enable the application of this approach in AF animal models to determine the feasibility, safety, and therapeutic implications. The project objective is to establish principles of optoelectronic control of cardiac rhythm and discover novel insights into AF mechanisms and treatment.

Objective

It’s my conviction that, one day, we will enable the human heart to terminate its own rhythm disturbances and thereby restore its normal rhythm at any place and time. Such acute restoration of cardiac rhythm would not be based on traumatizing electric shocks, but on generation of bioelectricity by the affected heart itself. In order to explore this paradigm-changing approach for ambulatory shock-free control of cardiac rhythm, I will integrate the unique advances of genetic engineering, computer modelling, tissue engineering and micro-optoelectronics. To determine the advanced and translational potential of such optoelectronic heart rhythm control, the most prevalent cardiac arrhythmia will be targeted, atrial fibrillation (AF).
To this purpose, we will first engineer human atrium-sized 3D models of AF from fully functional conditionally immortalized human atrial cardiomyocytes expressing light-gated ion channels. To realize and explore optoelectronic rhythm control in these models, customized multi-electrode-LED arrays (MELAs) will be integrated to gain full control over bioelectricity generation by precisely tailored illumination. Such illumination will be accomplished by a modular interactive optoelectronic system allowing continuous, accurate and realtime monitoring-based activation of specific LEDs in the MELAs. Insights from these studies will guide the application of this approach in pig models of AF to determine its feasibility, safety and therapeutic implications. From design to interpretation, all these studies will be supported by advanced computer simulations to realize an iterative process of optimization for maximum project outcome.
Establishing translational optoelectronic control of cardiac rhythm is expected to break new ground by revealing unique novel insights into AF mechanisms and management. This project could thus provide distinctively innovative therapeutic options, while generating novel tools and concepts in medical research and care.

Host institution

ACADEMISCH ZIEKENHUIS LEIDEN
Net EU contribution
€ 1 999 999,00
Address
ALBINUSDREEF 2
2333 ZA Leiden
Netherlands

See on map

Region
West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 999 999,00

Beneficiaries (1)